HS
LEGN icon

HighVista Strategies’s Legend Biotech LEGN Stock Holding History

HighVista Strategies’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36,385
Closed -$2.04M – 147
2024
Q1 		$2.04M Sell
36,385
-7,920
-18% -$478K 0.73% 46
2023
Q4 		$2.67M Hold
44,305
– – 0.97% 33
2023
Q3 		$2.98M Buy
44,305
+7,920
+22% +$550K 1.38% 18
2023
Q2 		$2.51M Buy
36,385
+27,943
+331% +$1.83M 1.15% 29
2023
Q1 		$407K Sell
8,442
-7,770
-48% -$380K 0.33% 77
2022
Q4 		$809K Buy
+16,212
New +$785K 0.48% 62

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

HighVista Strategies's LEGN Position: Q2 2024 in Review

HighVista Strategies sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 36,385 shares — an estimated $2.04M sold.

HighVista Strategies first reported a position in LEGN in Q4 2022 and held it in 6 quarters. The position peaked at $2.98M in Q3 2023. 181 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

  • HighVista Strategies reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
  • HighVista Strategies sold 36,385 Legend Biotech shares in Q2 2024, an estimated $2.04M.
  • HighVista Strategies first reported a position in Legend Biotech in Q4 2022 and held it in 6 quarters.
  • HighVista Strategies's Legend Biotech position peaked at $2.98M in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.